Organogenesis (NASDAQ:ORGO) Trading Down 5% – Time to Sell?

Organogenesis (NASDAQ:ORGO) shares fell 5% on Friday . The stock traded as low as $4.90 and last traded at $4.9210. 125,954 shares traded hands during trading, a decline of 92% from the average session volume of 1,553,580 shares. The stock had previously closed at $5.18.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ORGO shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Organogenesis in a research note on Monday, December 29th. BTIG Research reiterated a “buy” rating and issued a $9.00 price objective on shares of Organogenesis in a research note on Friday, December 26th. Finally, Wall Street Zen raised Organogenesis from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.00.

Organogenesis Price Performance

The firm’s 50 day moving average price is $5.15 and its two-hundred day moving average price is $4.68. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 2.88. The stock has a market cap of $588.86 million, a PE ratio of -38.67 and a beta of 1.38.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.07 by $0.11. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. The company had revenue of $150.86 million during the quarter, compared to the consensus estimate of $134.10 million. On average, research analysts expect that Organogenesis will post -0.07 earnings per share for the current year.

Insider Buying and Selling at Organogenesis

In related news, Director Glenn H. Nussdorf sold 200,000 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total transaction of $1,028,000.00. Following the sale, the director directly owned 2,565,591 shares in the company, valued at approximately $13,187,137.74. The trade was a 7.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 500,000 shares of company stock valued at $2,620,120 in the last three months. 33.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. State of Alaska Department of Revenue purchased a new stake in shares of Organogenesis in the third quarter worth about $25,000. Quarry LP bought a new stake in Organogenesis during the 3rd quarter worth approximately $25,000. Farther Finance Advisors LLC purchased a new stake in Organogenesis in the 2nd quarter worth approximately $35,000. Ground Swell Capital LLC bought a new position in Organogenesis in the 2nd quarter valued at $39,000. Finally, Walleye Capital LLC bought a new position in Organogenesis in the 2nd quarter valued at $45,000. Hedge funds and other institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.